Page last updated: 2024-11-13

jwh-122

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(4-methyl-1-naphthyl)-(1-pentylindol-3-yl)methanone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44466638
CHEMBL ID557004
SCHEMBL ID14774000
MeSH IDM0593682

Synonyms (34)

Synonym
CHEMBL557004 ,
jwh-122
A8575
619294-47-2
(4-methyl-1-naphthalenyl)(1-pentyl-1h-indol-3-yl)methanone
44147ri31x ,
(4-methyl-1-naphthyl)-(1-pentylindol-3-yl)methanone
unii-44147ri31x
dea no. 7122
bdbm50414070
FT-0673617
CCG-208713
AKOS022172514
SCHEMBL14774000
(4-methyl-1-naphthalenyl)(1-pentyl-1h-indol-3-yl)-methanone
4-methylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone
HUKJQMKQFWYIHS-UHFFFAOYSA-N
jwh-122 (1-pentyl-3-(4-methyl-1-napthoyl)indole)
1-pentyl-3-(4-methyl-1-naphthoyl) indole
j2.929.917j ,
methanone, (4-methyl-1-naphthalenyl)(1-pentyl-1h-indol-3-yl)-
DTXSID00210965
jwh 122
jwh-122; (4-methylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone
jwh-122 ((4-methylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone) 0.1 mg/ml in acetonitrile
jwh-122 ((4-methylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone)
jwh-122 ((4-methylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone) 1.0 mg/ml in acetonitrile
jwh122 /jwh122
BCP21287
(4-methylnaphthalen-1-yl)-(1-pentylindol-3-yl)methanone
jwh -122
Q2732651
jwh-122, 0.1mg/ml in methanol
jwh-122, 1mg/ml in methanol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The in vitro half-life was also determined in pooled human hepatocytes."( In Vitro Metabolism and Hepatic Intrinsic Clearance of the Synthetic Cannabinoid Receptor Agonist JWH-122 and Its Four ω-Halogenated Analogues.
Davidsen, AB; Linnet, K; Mardal, M, 2019
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 2 Homo sapiens (human)Ki0.00120.00000.415610.0000AID419195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID419196Selectivity ratio of pKi for CB1 receptor in rat brain to pKi for human cloned CB2 receptor2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID419197Selectivity ratio of pKi for human cloned CB2 receptor to pKi for CB1 receptor in rat brain2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID419195Displacement of [3H]CP-55940 from human cloned CB2 receptor by filtration assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID419194Displacement of [3H]CP-55940 from CB1 receptor in rat brain by filtration assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.26)29.6817
2010's16 (84.21)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.32 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index6.18 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]